Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327737 | 0.87 | ALDH1A1 (0.42) | PGRALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3328697 | 0.86 | PGR (0.40) | PGRALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13299663 | 0.83 | ALDH1A1 (0.43) | PGRALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3325321 | 0.83 | ALDH1A1 (0.41) | PGRALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3323851 | 0.83 | MAOB (0.51) | PGRALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3327584 | 0.82 | PGR (0.43) | PGRALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3326388 | 0.82 | ERCC1 (0.48) | PGRALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL981737 | 0.81 | ME2 (0.51) | PGRALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3323500 | 0.79 | ALDH1A1 (0.47) | PGRALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3326908 | 0.78 | PGR (0.40) | PGRALDH1A1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148865-B1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GENENTECH INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20100137394-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GRENENTECH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137394-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GRENENTECH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137394-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GRENENTECH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2008137408-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GENENTECH, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137394-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | WNT1, WNT3A, CTNNB1 | PGR 956/4885ALDH1A1 1479/4885HPGD 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.